Maryam Saberi-Karimian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maryam Saberi-Karimian has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Majid Ghayour-Mobarhan
International UNESCO Center for Health-Related Basic Sciences and Human Nutrition, Mashhad University of Medical Sciences, Mashhad, Iran
8 shared publications Gordon A. Ferns
Division of Medical Education Brighton & Sussex Medical School, Falmer Brighton BN1 9PH Sussex UK
7 shared publications- Habibollah Esmaily
Department of Biostatistics, School of Health, Mashhad University of Medical Sciences, Mashhad, Iran
4 shared publications Mohsen Moohebati
Heart and Vascular Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
3 shared publicationsSara Saffar Soflaei
Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
3 shared publications- Gordon A. Ferns
Division of Medical Education Brighton and Sussex Medical School Brighton UK
2 shared publications
Latest Publications
- Open Access
- 6 January 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (1)
The Association Between Height‐Related Novel Anthropometric Indices and Cardiovascular Events: A Cross‐Sectional Insight From the MASHAD Cohort Study
Background and Aims: Cardiovascular diseases (CVDs) are a worldwide health concern, with factors like poor nutrition and environmental conditions contributing to the burden of CVD and its mortality. Height and other anthropometric indices such as neck circumference (NC), hip circumference (HC), wrist circumference (WrC), waist‐to‐height ratio (WHtR), and mid‐upper arm circumference (MUAC) have been associated with CVD, cardiometabolic risk, and CVD mortality. However, there is a lack of comprehensive research on the relationship between height and height‐related indices. This study aimed to investigate the relationship between height‐related novel anthropometric indices and the incidence of CVD. Methods: This cross‐sectional study investigated the association between novel height‐related anthropometric indices and the incidence of CVD among participants in phase II of the Mashhad Stroke and Heart Atherosclerotic Disorders (MASHAD) cohort study. The anthropometric indices measured included body mass index (BMI), WHtR, hip to height ratio (HHR), wrist to height ratio (WrHR), neck to height ratio (NHR), and mid‐arm to height ratio (MAHR). The study population was divided into two groups: healthy individuals and those with CVD. Results: A total of 7113 individuals participated in the study. Of these, 88.2% were healthy, and 11.8% had CVD. Multivariable logistic regression analysis unveiled a significant 2.4% decrease in CVD odds as one percent decrease in WHtR in men [OR:1.024 (1.001–1.047), p ‐value = 0.039], but no significant association was found in women after accounting for confounding factors ( p ‐value > 0.05). Conclusion: Our study identified WHtR as a significant predictor of CVD incidence in men, highlighting its potential as an effective indicator for CVD risk. Meanwhile, the lack of a significant relationship between height and other anthropometric indices with CVD risk in women may suggest confounder effects and also a need for further investigation into the relationship between these indices and CVD risk in females in a larger sample size.
- 6 January 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (1)
Open AccessThe Association Between Height‐Related Novel Anthropometric Indices and Cardiovascular Events: A Cross‐Sectional Insight From the MASHAD Cohort Study
Background and Aims: Cardiovascular diseases (CVDs) are a worldwide health concern, with factors like poor nutrition and environmental conditions contributing to the burden of CVD and its mortality. Height and other anthropometric indices such as neck circumference (NC), hip circumference (HC), wrist circumference (WrC), waist‐to‐height ratio (WHtR), and mid‐upper arm circumference (MUAC) have been associated with CVD, cardiometabolic risk, and CVD mortality. However, there is a lack of comprehensive research on the relationship between height and height‐related indices. This study aimed to investigate the relationship between height‐related novel anthropometric indices and the incidence of CVD. Methods: This cross‐sectional study investigated the association between novel height‐related anthropometric indices and the incidence of CVD among participants in phase II of the Mashhad Stroke and Heart Atherosclerotic Disorders (MASHAD) cohort study. The anthropometric indices measured included body mass index (BMI), WHtR, hip to height ratio (HHR), wrist to height ratio (WrHR), neck to height ratio (NHR), and mid‐arm to height ratio (MAHR). The study population was divided into two groups: healthy individuals and those with CVD. Results: A total of 7113 individuals participated in the study. Of these, 88.2% were healthy, and 11.8% had CVD. Multivariable logistic regression analysis unveiled a significant 2.4% decrease in CVD odds as one percent decrease in WHtR in men [OR:1.024 (1.001–1.047), p ‐value = 0.039], but no significant association was found in women after accounting for confounding factors ( p ‐value > 0.05). Conclusion: Our study identified WHtR as a significant predictor of CVD incidence in men, highlighting its potential as an effective indicator for CVD risk. Meanwhile, the lack of a significant relationship between height and other anthropometric indices with CVD risk in women may suggest confounder effects and also a need for further investigation into the relationship between these indices and CVD risk in females in a larger sample size.
- Open Access
- 26 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Exploring the association between pulse wave velocity and CKD progression: a longitudinal study in Mashhad, Iran
This research is distinctive in its emphasis on non-invasive arterial stiffness as a critical vascular risk factor for renal failure. Our objective was to evaluate this correlation through both invasive and non-invasive techniques, representing an innovative strategy in the discipline. The study took place in Mashhad, Iran, and was specifically designed to investigate the association between diminished glomerular filtration rate (GFR) and arterial stiffness. We performed an extensive analysis involving 787 participants aged between 35 and 65, who were randomly selected from the Mashhad Stroke and Heart Atherosclerotic Disorder (MASHAD) cohort study. We carefully documented the baseline characteristics of these participants, which encompassed demographic information, biochemical and hematological markers, as well as measurements of systolic and diastolic blood pressure, and indicators of arterial stiffness, including pulse wave velocity (PWV), central augmentation index (CAI), and central aortic pressure (CAP). The participants were categorized into four groups according to their serum creatinine and estimated GFR-MDRD levels: Group 1 (GFR: 60–89), Group 2 (GFR: 45–59), Group 3 (GFR: 30–44), and Group 4 (GFR: 15–29) based on clinical practice guidelines for chronic kidney disease. The velocity of pulse waves exhibited a notable increase as the estimated GFR decreased, reaching its peak in Group 4 (9.92 ± 4.29 m/s) and its lowest point in Group 2 (6.9 ± 2.35 m/s) (P < 0.05). No significant variations were detected in CAP, CAI, and GFR across the study groups. Two analytical models were employed to evaluate the relationship between arterial stiffness markers and different stages of chronic kidney disease (CKD). The first model (unadjusted data) revealed a significant correlation between Group 3b and CAP (P = 0.034), as well as between Group 4 and PWV (P = 0.021). In the second model (adjusted for sex, age, hypertension, and diabetes), a significant correlation persisted between Group 4 and PWV (P = 0.049). The results of this research highlight the importance of arterial stiffness as a marker of deteriorating kidney function. The study concluded that PWV is associated with a reduction in eGFR, indicating that each unit rise in PWV corresponds to a 41.8% decline in eGFR. It is advisable for subsequent research to investigate the mechanisms that link arterial stiffness to impaired kidney function.
- 26 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessExploring the association between pulse wave velocity and CKD progression: a longitudinal study in Mashhad, Iran
This research is distinctive in its emphasis on non-invasive arterial stiffness as a critical vascular risk factor for renal failure. Our objective was to evaluate this correlation through both invasive and non-invasive techniques, representing an innovative strategy in the discipline. The study took place in Mashhad, Iran, and was specifically designed to investigate the association between diminished glomerular filtration rate (GFR) and arterial stiffness. We performed an extensive analysis involving 787 participants aged between 35 and 65, who were randomly selected from the Mashhad Stroke and Heart Atherosclerotic Disorder (MASHAD) cohort study. We carefully documented the baseline characteristics of these participants, which encompassed demographic information, biochemical and hematological markers, as well as measurements of systolic and diastolic blood pressure, and indicators of arterial stiffness, including pulse wave velocity (PWV), central augmentation index (CAI), and central aortic pressure (CAP). The participants were categorized into four groups according to their serum creatinine and estimated GFR-MDRD levels: Group 1 (GFR: 60–89), Group 2 (GFR: 45–59), Group 3 (GFR: 30–44), and Group 4 (GFR: 15–29) based on clinical practice guidelines for chronic kidney disease. The velocity of pulse waves exhibited a notable increase as the estimated GFR decreased, reaching its peak in Group 4 (9.92 ± 4.29 m/s) and its lowest point in Group 2 (6.9 ± 2.35 m/s) (P < 0.05). No significant variations were detected in CAP, CAI, and GFR across the study groups. Two analytical models were employed to evaluate the relationship between arterial stiffness markers and different stages of chronic kidney disease (CKD). The first model (unadjusted data) revealed a significant correlation between Group 3b and CAP (P = 0.034), as well as between Group 4 and PWV (P = 0.021). In the second model (adjusted for sex, age, hypertension, and diabetes), a significant correlation persisted between Group 4 and PWV (P = 0.049). The results of this research highlight the importance of arterial stiffness as a marker of deteriorating kidney function. The study concluded that PWV is associated with a reduction in eGFR, indicating that each unit rise in PWV corresponds to a 41.8% decline in eGFR. It is advisable for subsequent research to investigate the mechanisms that link arterial stiffness to impaired kidney function.
- Open Access
- 1 December 2025
- Published by Maad Rayan Publishing Company in International Journal of Infectious Diseases
- Vol. 28 (12) , 723-736
Association of Serum Lipids with 10-Year CVD and All-Cause Mortality in Iranian Adults: A Prospective Cohort Study
Background: Individuals with abnormal serum lipid levels are at an augmented risk of atherosclerotic cardiovascular diseases (CVDs). The purpose of this study was to evaluate the significance of serum lipid concentrations as determinants for the risk of CVD and all-cause mortality (ACM). Methods: This prospective cohort study involved individuals who were part of the Mashhad stroke and heart atherosclerotic disorder (MASHAD) study initiated in 2007. A total of 9704 individuals aged 35- 65 years were involved in the current study. The participants were monitored for about a decade to track mortality and its underlying causes. Multivariable Cox proportional hazards models were applied to estimate hazard ratios (HRs) for serum levels of LDL-C, HDL-C, non-HDL-C, and triglycerides (TG), analyzed both as continuous variables and categorized into tertiles. Three models were developed: Model 1 (unadjusted), Model 2 (adjusted for age and sex), and Model 3 (further adjusted for BMI, smoking status, diabetes, hypertension, CVD, job, marital status, education level, and lipid-lowering drugs use). Kaplan–Meier survival analysis compared outcomes across lipid tertiles. Subgroup analyses were also performed to evaluate and control for confounding variables related to serum lipid levels and mortality. Results: Over a follow-up period of 10 years, there were 429 (4.4%) deaths, including 185 cases due to CVD and 124 cases due to cancer. LDL-C, HDL-C, non-HDL cholesterol, and TG were categorized into three groups based on tertiles. Based on Cox model analysis, after full adjustment, individuals in the second (37.9–45.8 mg/dL) and third (45.8–96.2 mg/dL) tertiles of HDL-C had a significantly lower risk of ACM compared with the lowest tertile (≤37.9 mg/dL) (HR=0.72, 95% CI: 0.57–0.92; and HR=0.81, 95% CI: 0.64–1.03, respectively). Similarly, the risk of cardiovascular mortality was reduced in the second tertile (HR=0.66, 95% CI: 0.46–0.94). No significant associations were found between LDL-C and mortality after adjustment. Kaplan–Meier analyses confirmed significant survival differences across HDL-C (P value=0.005), TG (P value=0.001), and non-HDL-C (P value<0.001) tertiles for ACM event. Significant differences were also observed in the Kaplan–Meier curves for cardiovascular death between HDL-C (P value=0.003) and TG groups (P value=0.015). The survival curves of HDL-C groups were significantly variable in terms of cancer mortality (P value=0.048). In exploratory subgroup analyses, the inverse correlation between elevated HDL-C levels and mortality was predominantly more pronounced in older people and those with hypertension or diabetes, whereas it was less significant in younger and healthier individuals. Conclusion: Abnormal levels of serum lipids, specifically low HDL-C concentration, are associated with an elevated risk of both non-CVD and CVD mortality. These relationships were widely seen across clinical categories, exhibiting substantially greater patterns in older participants and in persons with hypertension or diabetes. These findings indicate that HDL-C may assist in identifying individuals at increased mortality risk within this population.
- 1 December 2025
- Published by Maad Rayan Publishing Company in International Journal of Infectious Diseases
- Vol. 28 (12) , 723-736
Open AccessAssociation of Serum Lipids with 10-Year CVD and All-Cause Mortality in Iranian Adults: A Prospective Cohort Study
Background: Individuals with abnormal serum lipid levels are at an augmented risk of atherosclerotic cardiovascular diseases (CVDs). The purpose of this study was to evaluate the significance of serum lipid concentrations as determinants for the risk of CVD and all-cause mortality (ACM). Methods: This prospective cohort study involved individuals who were part of the Mashhad stroke and heart atherosclerotic disorder (MASHAD) study initiated in 2007. A total of 9704 individuals aged 35- 65 years were involved in the current study. The participants were monitored for about a decade to track mortality and its underlying causes. Multivariable Cox proportional hazards models were applied to estimate hazard ratios (HRs) for serum levels of LDL-C, HDL-C, non-HDL-C, and triglycerides (TG), analyzed both as continuous variables and categorized into tertiles. Three models were developed: Model 1 (unadjusted), Model 2 (adjusted for age and sex), and Model 3 (further adjusted for BMI, smoking status, diabetes, hypertension, CVD, job, marital status, education level, and lipid-lowering drugs use). Kaplan–Meier survival analysis compared outcomes across lipid tertiles. Subgroup analyses were also performed to evaluate and control for confounding variables related to serum lipid levels and mortality. Results: Over a follow-up period of 10 years, there were 429 (4.4%) deaths, including 185 cases due to CVD and 124 cases due to cancer. LDL-C, HDL-C, non-HDL cholesterol, and TG were categorized into three groups based on tertiles. Based on Cox model analysis, after full adjustment, individuals in the second (37.9–45.8 mg/dL) and third (45.8–96.2 mg/dL) tertiles of HDL-C had a significantly lower risk of ACM compared with the lowest tertile (≤37.9 mg/dL) (HR=0.72, 95% CI: 0.57–0.92; and HR=0.81, 95% CI: 0.64–1.03, respectively). Similarly, the risk of cardiovascular mortality was reduced in the second tertile (HR=0.66, 95% CI: 0.46–0.94). No significant associations were found between LDL-C and mortality after adjustment. Kaplan–Meier analyses confirmed significant survival differences across HDL-C (P value=0.005), TG (P value=0.001), and non-HDL-C (P value<0.001) tertiles for ACM event. Significant differences were also observed in the Kaplan–Meier curves for cardiovascular death between HDL-C (P value=0.003) and TG groups (P value=0.015). The survival curves of HDL-C groups were significantly variable in terms of cancer mortality (P value=0.048). In exploratory subgroup analyses, the inverse correlation between elevated HDL-C levels and mortality was predominantly more pronounced in older people and those with hypertension or diabetes, whereas it was less significant in younger and healthier individuals. Conclusion: Abnormal levels of serum lipids, specifically low HDL-C concentration, are associated with an elevated risk of both non-CVD and CVD mortality. These relationships were widely seen across clinical categories, exhibiting substantially greater patterns in older participants and in persons with hypertension or diabetes. These findings indicate that HDL-C may assist in identifying individuals at increased mortality risk within this population.
- Open Access
- 2 October 2025
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 8 (6) , e70108
Association Between Serum Syndecan 1 Levels and Metabolic Syndrome Parameters: A Comparative Cross‐Sectional Study
Introduction: Previous studies have linked Syndecans (SDCs) to hypertension (HTN), BMI and the prevalence of coronary artery disease (CAD). The relationship between SDCs and metabolic syndrome (MetS) has not been explored. This study aimed to investigate the association between serum SDC1 level and MetS. Methods: This was a comparative cross‐sectional study conducted on the subjects from phase II of the MASHAD study. A total of 81 subjects were divided into three groups: (1) healthy controls ( N = 26), (2) subjects with MetS and hypertension with serum ALT < 43 U/L (MetS+ HTN+ ALT–), ( N = 29), and (3) subjects with MetS and hypertension with serum ALT ≥ 43 U/L (MetS+ HTN+ ALT+), ( N = 26). Serum SDC1 levels were measured using a commercial ELISA kit. Data were analysed using SPSS version 26 and R version 4.0.5 software. Results: The analysis showed that mean serum SDC1 levels did not significantly differ between healthy and MetS+ groups overall. Among MetS+ subjects, males had significantly higher SDC1 levels than females (17.57 ± 8.48 vs. 12.85 ± 5.59 ng/mL, p = 0.018). In the MetS+ HTN+ ALT+ group, males also had higher SDC1 levels compared to females (20.19 ± 10.56 vs. 11.82 ± 5.09 ng/mL, p = 0.020), while no significant differences were observed across the MetS groups overall ( p = 0.474). Additionally, in both the total study sample and the MetS+ HTN+ ALT+ group, SDC1 levels were positively correlated with diastolic blood pressure (DBP) ( r = 0.256, p = 0.021; r = 0.463, p = 0.017, respectively), with no significant associations found with other metabolic parameters. Conclusions: These findings suggest that SDC1 levels are higher in males with MetS, particularly those with hypertension and elevated ALT, and are positively associated with DBP in both the total study sample and the MetS+ HTN+ ALT+ group. There were no significant associations with other metabolic parameters. This indicates that SDC1 may serve as a gender‐specific biomarker for vascular risk in MetS, potentially aiding clinicians in identifying high‐risk MetS subjects.
- 2 October 2025
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 8 (6) , e70108
Open AccessAssociation Between Serum Syndecan 1 Levels and Metabolic Syndrome Parameters: A Comparative Cross‐Sectional Study
Introduction: Previous studies have linked Syndecans (SDCs) to hypertension (HTN), BMI and the prevalence of coronary artery disease (CAD). The relationship between SDCs and metabolic syndrome (MetS) has not been explored. This study aimed to investigate the association between serum SDC1 level and MetS. Methods: This was a comparative cross‐sectional study conducted on the subjects from phase II of the MASHAD study. A total of 81 subjects were divided into three groups: (1) healthy controls ( N = 26), (2) subjects with MetS and hypertension with serum ALT < 43 U/L (MetS+ HTN+ ALT–), ( N = 29), and (3) subjects with MetS and hypertension with serum ALT ≥ 43 U/L (MetS+ HTN+ ALT+), ( N = 26). Serum SDC1 levels were measured using a commercial ELISA kit. Data were analysed using SPSS version 26 and R version 4.0.5 software. Results: The analysis showed that mean serum SDC1 levels did not significantly differ between healthy and MetS+ groups overall. Among MetS+ subjects, males had significantly higher SDC1 levels than females (17.57 ± 8.48 vs. 12.85 ± 5.59 ng/mL, p = 0.018). In the MetS+ HTN+ ALT+ group, males also had higher SDC1 levels compared to females (20.19 ± 10.56 vs. 11.82 ± 5.09 ng/mL, p = 0.020), while no significant differences were observed across the MetS groups overall ( p = 0.474). Additionally, in both the total study sample and the MetS+ HTN+ ALT+ group, SDC1 levels were positively correlated with diastolic blood pressure (DBP) ( r = 0.256, p = 0.021; r = 0.463, p = 0.017, respectively), with no significant associations found with other metabolic parameters. Conclusions: These findings suggest that SDC1 levels are higher in males with MetS, particularly those with hypertension and elevated ALT, and are positively associated with DBP in both the total study sample and the MetS+ HTN+ ALT+ group. There were no significant associations with other metabolic parameters. This indicates that SDC1 may serve as a gender‐specific biomarker for vascular risk in MetS, potentially aiding clinicians in identifying high‐risk MetS subjects.
- Open Access
- 12 February 2025
- Published by Elsevier in Neurobiology of Sleep and Circadian Rhythms
- Vol. 18, 100113
Association of restless legs syndrome and obesity: A sub-population of the MASHAD cohort study
- 12 February 2025
- Published by Elsevier in Neurobiology of Sleep and Circadian Rhythms
- Vol. 18, 100113
Open AccessAssociation of restless legs syndrome and obesity: A sub-population of the MASHAD cohort study
- 27 September 2024
- Published by Springer Nature in The Cerebellum
- Vol. 23 (6) , 2607-2615
The Latest Developments for the Treatment of Ataxia Telangiectasia: A Narrative Review
Ataxia telangiectasia (AT), Louis-Bar syndrome, is a rare neurodegenerative disorder caused by autosomal recessive biallelic mutations within the ataxia telangiectasia mutated (ATM) gene. Currently, there are no curative therapies available for this disorder. This review provides an overview of the latest advances in treatment methods including 1- Acetyl-DL-leucine, 2- Bone Marrow Transplantation, 3- Gene Therapy, 4- Dexamethasone, and finally 5- Red Blood Cells (RBCs) as a carrier for dexamethasone (encapsulation of dexamethasone sodium phosphate into autologous erythrocytes, known as EryDex). Most of the treatments under investigation are in the early stages, except for the EryDex System. It appears that the EryDex system and N-Acetyl-DL-Leucine may hold promise as potential treatment options.
- 27 September 2024
- Published by Springer Nature in The Cerebellum
- Vol. 23 (6) , 2607-2615
The Latest Developments for the Treatment of Ataxia Telangiectasia: A Narrative Review
Ataxia telangiectasia (AT), Louis-Bar syndrome, is a rare neurodegenerative disorder caused by autosomal recessive biallelic mutations within the ataxia telangiectasia mutated (ATM) gene. Currently, there are no curative therapies available for this disorder. This review provides an overview of the latest advances in treatment methods including 1- Acetyl-DL-leucine, 2- Bone Marrow Transplantation, 3- Gene Therapy, 4- Dexamethasone, and finally 5- Red Blood Cells (RBCs) as a carrier for dexamethasone (encapsulation of dexamethasone sodium phosphate into autologous erythrocytes, known as EryDex). Most of the treatments under investigation are in the early stages, except for the EryDex System. It appears that the EryDex system and N-Acetyl-DL-Leucine may hold promise as potential treatment options.
- Open Access
- 22 May 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (10) , e7225
The association of preoperative hematologic parameters with short‐term clinical outcomes in rectal cancer: A feature importance analysis
Background: Various hematologic parameters have been proposed as prognostic factors in rectal cancer management, but data are conflicting and unclear. This study is designed to investigate the prognostic factor capability of preoperative hematologic parameters with postoperative morbidities and mortality in rectal cancer patients undergoing curative resection.Methods: All 200 consecutive rectal cancer patients diagnosed at Ghaem University Hospital from 2017 to 2022 were retrospectively evaluated. The receiver operating characteristic (ROC) curves and machine learning (ML) algorithms of Random Forest, Recursive Feature Elimination, simulated annealing, Support Vector Machine, Decision Tree, and eXtreme Gradient Boosting were administered to investigate the role of preoperative hematologic parameters accompanied by baseline characteristics on three clinical outcomes including surgical infectious complications, recurrence, and death.Results: The frequency of infectious complications was correlated with the surgical procedure, while tumor recurrence was significantly influenced by T stage and N stage. In terms of mortality, alongside T and N stage, the status of resection margin involvement was significantly correlated. Based on the ROC analysis, the NLR >2.69, MPV ≤9 fL, and PDW ≤10.5 fL were more classified patients to mortality status. Likewise, the PLT >220 109/L, MPV ≤9 fL, PDW ≤10.4 fL, and PLR >13.6 were correlated with recurrence. However, all factors examined in this study were not significant classifiers for the outcome of surgical infectious complications. The results of ML algorithms were also in line with ROC analysis.Conclusion: According to the results of both ROC analysis and ML models, preoperative hematologic parameters are considerable prognostic factors of postoperative outcomes in rectal cancer patients, and are recommended to be monitored by clinicians to prevent unfavorable outcomes.
- 22 May 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (10) , e7225
Open AccessThe association of preoperative hematologic parameters with short‐term clinical outcomes in rectal cancer: A feature importance analysis
Background: Various hematologic parameters have been proposed as prognostic factors in rectal cancer management, but data are conflicting and unclear. This study is designed to investigate the prognostic factor capability of preoperative hematologic parameters with postoperative morbidities and mortality in rectal cancer patients undergoing curative resection.Methods: All 200 consecutive rectal cancer patients diagnosed at Ghaem University Hospital from 2017 to 2022 were retrospectively evaluated. The receiver operating characteristic (ROC) curves and machine learning (ML) algorithms of Random Forest, Recursive Feature Elimination, simulated annealing, Support Vector Machine, Decision Tree, and eXtreme Gradient Boosting were administered to investigate the role of preoperative hematologic parameters accompanied by baseline characteristics on three clinical outcomes including surgical infectious complications, recurrence, and death.Results: The frequency of infectious complications was correlated with the surgical procedure, while tumor recurrence was significantly influenced by T stage and N stage. In terms of mortality, alongside T and N stage, the status of resection margin involvement was significantly correlated. Based on the ROC analysis, the NLR >2.69, MPV ≤9 fL, and PDW ≤10.5 fL were more classified patients to mortality status. Likewise, the PLT >220 109/L, MPV ≤9 fL, PDW ≤10.4 fL, and PLR >13.6 were correlated with recurrence. However, all factors examined in this study were not significant classifiers for the outcome of surgical infectious complications. The results of ML algorithms were also in line with ROC analysis.Conclusion: According to the results of both ROC analysis and ML models, preoperative hematologic parameters are considerable prognostic factors of postoperative outcomes in rectal cancer patients, and are recommended to be monitored by clinicians to prevent unfavorable outcomes.
- 30 April 2024
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 368 (2) , 99-111
Syndecans and diabetic complications: a narrative review
- 30 April 2024
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 368 (2) , 99-111
Syndecans and diabetic complications: a narrative review